These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28466570)

  • 21. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex.
    Zhou Z; Rademaker AW; Gordon LI; LaCasce AS; Crosby-Thompson A; Vanderplas A; Abel GA; Rodriguez MA; Nademanee A; Kaminski MS; Czuczman MS; Millenson MM; Zelenetz AD; Niland J; Friedberg JW; Winter JN
    J Natl Compr Canc Netw; 2016 Oct; 14(10):1274-1281. PubMed ID: 27697981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma.
    Sanfilippo KM; Wang TF; Gage BF; Luo S; Riedell P; Carson KR
    Thromb Res; 2016 Jul; 143():86-90. PubMed ID: 27208462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era.
    Sarkozy C; Camus V; Tilly H; Salles G; Jardin F
    Leuk Lymphoma; 2015 Jul; 56(7):1959-68. PubMed ID: 25363401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
    Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L
    J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FilGAP, a Rac-specific Rho GTPase-activating protein, is a novel prognostic factor for follicular lymphoma.
    Nishi T; Takahashi H; Hashimura M; Yoshida T; Ohta Y; Saegusa M
    Cancer Med; 2015 Jun; 4(6):808-18. PubMed ID: 25641953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression.
    Saito B; Shiozawa E; Yamochi-Onizuka T; Adachi D; Nakamaki T; Tomoyasu S; Omine M; Mitsuya T; Takimoto M; Ota H
    Pathol Int; 2004 Sep; 54(9):667-74. PubMed ID: 15363034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary gastrointestinal follicular lymphoma: single-center 12-year experiences.
    Na YJ; Kim ER; Kim SJ; Kim WS; Ko YH; Son HJ
    Hepatogastroenterology; 2012 May; 59(115):751-3. PubMed ID: 22020908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
    Okina S; Yanagisawa N; Yokoyama M; Sakurai Y; Numata Y; Umezawa A; Higashihara M; Murakumo Y
    Int J Hematol; 2015 Dec; 102(6):662-9. PubMed ID: 26449786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study.
    Ritter AJ; Goldstein JS; Ayers AA; Flowers CR
    Leuk Lymphoma; 2019 Jul; 60(7):1656-1667. PubMed ID: 30632824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
    Prochazka KT; Melchardt T; Posch F; Schlick K; Deutsch A; Beham-Schmid C; Weiss L; Gary T; Neureiter D; Klieser E; Greil R; Neumeister P; Egle A; Pichler M
    Br J Cancer; 2016 Nov; 115(10):1264-1272. PubMed ID: 27764838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
    Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
    Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adolescent weight and height are predictors of specific non-Hodgkin lymphoma subtypes among a cohort of 2,352,988 individuals aged 16 to 19 years.
    Leiba M; Leiba A; Keinan-Boker L; Avigdor A; Derazne E; Levine H; Kark JD
    Cancer; 2016 Apr; 122(7):1068-77. PubMed ID: 26900677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
    Batlevi CL; Crump M; Andreadis C; Rizzieri D; Assouline SE; Fox S; van der Jagt RHC; Copeland A; Potvin D; Chao R; Younes A
    Br J Haematol; 2017 Aug; 178(3):434-441. PubMed ID: 28440559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis.
    Ochi Y; Hiramoto N; Ono Y; Yoshioka S; Tabata S; Yonetani N; Matsushita A; Imai Y; Ishikawa T
    Leuk Lymphoma; 2016 Aug; 57(8):1945-8. PubMed ID: 26689650
    [No Abstract]   [Full Text] [Related]  

  • 38. Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5).
    Mounier M; Bossard N; Remontet L; Belot A; Minicozzi P; De Angelis R; Capocaccia R; Iwaz J; Monnereau A; Troussard X; Sant M; Maynadié M; Giorgi R; ;
    Lancet Haematol; 2015 Nov; 2(11):e481-91. PubMed ID: 26686258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
    Slack GW; Steidl C; Sehn LH; Gascoyne RD
    Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
    Strüßmann T; Fritsch K; Baumgarten A; Fietz T; Engelhardt M; Mertelsmann R; Ihorst G; Duyster J; Finke J; Marks R
    Br J Haematol; 2017 Sep; 178(6):927-935. PubMed ID: 28643323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.